Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
LAS VEGAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced it is hosting an informational luncheon presentation in Jeddah, the Kingdom of Saudi Arabia about its medical discoveries for the treatment of Parkinson’s disease.
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the treatment of Parkinson’s disease, at the 30 interim examination had a 50% improvement in their motor skills. Zhittya’s study utilized their human FGF-1 biological drug candidate in conjunction with a proprietary intranasal delivery device to introduce its medicine into the brain. Previous preclinical work established that twice the amount of FGF-1 could be delivered into the brain via the intranasal route versus the intravenous route. Intranasal dosing started on human test subjects on May 3, 2022 and concluded on May 30, 2022 with the patients receiving two escalating doses of intranasal FGF-1. No adverse events to date have been seen in the subjects and analysis of videos taken before and after treatment showed promising signs of motor skill improvement, according to the test subjects and the Principal Investigator supervising the trial. Additional follow-up sessions will occur at 60-days and 90-days post-treatment to assess any adverse events that may have appeared and to document any continued progress towards reversing the test subjects' Parkinson's disease.
LAS VEGAS, June 08, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it has completed its first-in-human research study for the treatment of Parkinson’s disease. Zhittya’s study utilized their human FGF-1 biological drug candidate in conjunction with a proprietary intranasal delivery device to introduce its medicine into the brain.